Hypothesis: Maintaining CB₁‑dependent ZO‑1 expression in the distal small intestine during mid‑life prevents the downstream rise in systemic inflammatory markers that characterizes inflammaging.

Mechanistic basis

Age‑related loss of CB₁ in the distal small intestine lifts repression of miR‑191‑5p and activates NF‑κB p65, which together suppress ZO‑1 transcription 3. Reduced ZO‑1 weakens the tight‑ junction seal, allowing increased translocation of bacterial ligands such as LPS and peptidoglycan. These microbial‑associated molecular patterns engage TLR4 on lamina propria dendritic cells, triggering local release of IL‑6 and TNF‑α that spill into the circulation and sustain a low‑grade inflammatory state 2,4. Importantly, ZO‑1 also scaffolds actin‑binding proteins that restrain RhoA/ROCK‑mediated contractility; its loss increases myosin II‑driven tension, further destabilizing junctions independent of protein levels (see the Myosin II Contractile Trigger discussion). By preserving CB₁ signaling, ZO‑1 levels remain sufficient to both seal the paracellular pathway and curb excessive cytoskeletal tension, thereby blocking the initial microbial‑triggered inflammatory cascade.

Testable predictions

1. Longitudinal CB₁ agonist treatment in mice starting at 12 months of age will preserve distal‑small‑intestinal ZO‑1 and occludin levels, reduce serum LPS‑binding protein, and attenuate the age‑associated increase in circulating IL‑6 and TNF‑α compared with vehicle controls.
2. Conditional knockout of CB₁ restricted to intestinal epithelial cells will accelerate the appearance of serum zonulin and cytokine elevations, even when colonic ZO‑1 remains intact, highlighting the distal small intestine as the critical early site.
3. Pharmacologic inhibition of myosin II ATPase (blebbistatin) in CB₁‑deficient mice will rescue barrier permeability without restoring ZO‑1, demonstrating that contractile tension contributes independently to inflammaging.

Potential confounders and controls

• Microbiota composition shifts with age; experiments will include cohousing or fecal transplant controls to isolate barrier effects.
• Off‑target effects of CB₁ agonists will be monitored using CB₁‑null littermates.
• Serum zonulin will be measured alongside functional permeability assays (FITC‑dextran) to validate the biomarker.

Experimental outline

• Cohort: C57BL/6 mice, n=15 per group, treated from 12 mo to 24 mo.
• Groups: vehicle, CB₁ agonist (ACEA), CB₁ agonist + myosin II inhibitor, epithelial‑specific CB₁ KO, and WT.
• Readouts: intestinal ZO‑1/occludin immunofluorescence, transepithelial resistance ex vivo, serum LPS‑binding protein, IL‑6, TNF‑α, zonulin, and histological inflammation scores.
• Statistical analysis: two‑way ANOVA with post‑hoc Tukey; significance set at p<0.05.

If CB₁‑mediated ZO‑1 preservation delays the rise of systemic inflammatory markers, the hypothesis is supported; failure to observe such protection would falsify the claim that distal small‑intestinal barrier integrity is a primary driver of inflammaging.